Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News Alert: FDA, FTC warn 10 companies for making ‘fraudulent claims’ about unapproved diabetes supplements

News You Need to Know Today
News Alert: FDA, FTC warn 10 companies for making ‘fraudulent claims’ about unapproved diabetes supplements
Thursday, September 9, 2021
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

News Alert

FDA, FTC warn 10 companies for making ‘fraudulent claims’ about unapproved diabetes supplements

Each company is believed to be in violation of the Federal Food, Drug and Cosmetic Act. They have 15 working days to respond. 

READ MORE >
pills-384846_960_720.jpg
Share on Twitter Share on Facebook Share on Linkedin

FDA, FTC warn 10 companies for making ‘fraudulent claims’ about unapproved diabetes supplements

Share on Twitter Share on Facebook Share on Linkedin
pills-384846_960_720.jpg
Each company is believed to be in violation of the Federal Food, Drug and Cosmetic Act. They have 15 working days to respond. 
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Top 10 most popular cardiology video interviews this past month
Week in Review: CCTA on ACC expo floor gives cardiologist wake-up call | Reaction to CMS TAVR changes | Recalls and new AI
CCTA scan provides a wake-up call | Resistance training & heart attack risk in women | New ultrasound tech | AFib & grout
FDA clears first surgical valve of its kind | Family files $17M lawsuit | BATMAN to the rescue | Major trends at SCCT 2026
Early reactions to proposed TAVR changes | Cardiology still an AI leader | More than 11K bottles of blood pressure drug recalled
TV star's family awarded $13M in malpractice case | Helping patients with ‘broken hearts’ | Cardiac amyloidosis in the spotlight
CMS proposes major TAVR changes | The real impact of RVU cuts in electrophysiology | Girl’s heart valve implanted upside down

Pagination

    • Current page 1
    • Page 2
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9 …
    • Next page ››
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme